Stengone Carmine N. 4

What Happened
Carmine N. Stengone, CEO, President and Director of Contineum Therapeutics (CTNM), received a grant of 445,000 derivative shares (options) on January 30, 2026. The Form 4 reports an acquisition price of $0.00, reflecting an option award rather than an open‑market purchase; the filing does not state an immediate cash value or exercise (strike) price.

Key Details

• Transaction date: 2026-01-30; Form filed 2026-01-30 (timely).
• Transaction type/code: A — Award/Grant (derivative).
• Shares/rights granted: 445,000 option shares. Reported acquisition price: $0.00 (indicates option award).
• Vesting: Options vest in equal monthly installments over 48 months, subject to continuous service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• No tax withholding, sale, or 10b5-1 plan mentioned in this filing.

Context
This is a standard executive equity incentive grant: it creates the potential for future ownership if options vest and are exercised. The Form 4 does not disclose an exercise/strike price or immediate realized value, so the grant’s monetary value isn’t determinable from this filing alone. Grants like this are common for aligning executives’ incentives with long‑term company performance.